The Bulletin of the American College of Surgeons is the College’s member magazine. Each issue, the ACS Cancer Research Program authors a column in the Bulletin related to clinical trials in cancer. Feature articles on certain clinical research topics are also published periodically.
2024
Social Determinants of Health Screening Influence Cancer Outcomes (July, 2024)
Observations from Breast Patients Reveal Barriers Achieving Timely Care (May, 2024)
2023
Cancer QI Initiative Helps Increase Treatment Compliance (December 2023, Column)
NAPRC Stays the Course in Quest to Improve Rectal Cancer Care (September 2023, Column)
Cancer Research Program Redefines Its Role To Advance Care For Surgical Cancer Patients (July 2023, Column)
New Educational Resource on Cancer Surgery Protocols Is Available (May 2023, Column)
Mutational Profiling Using Circulating Tumor DNA Helps Guide Treatment Decisions for Patients with Colorectal Cancer (March 2023, Column)
Quality Improvement Initiative Takes on Smoking among Cancer Patients (February 2023, Column)
Today’s National Cancer Database Is Key to a Better Tomorrow (January 2023, Column)
2022
New Standards Offer Glimpse of Multidisciplinary Care through the Lens of the Breast Cancer Patient (November-December 2022 Column)
Genetic and Genomic Testing and Implications in Treatment for Pancreatic Adenocarcinoma: What All Surgeons Should Know (October 2022, Column)
New Volume of Cancer Surgery Recommendations Released (September 2022, Column)
Studying Patient-Reported Observations on Timeliness of Breast Services (August 2022, Column)
ALLIANCE A021806: A Phase III Trial of Perioperative vs. Adjuvant Chemotherapy for Resectable Pancreatic Cancer (July 2022, column)
To Operate or Not in De Novo Stage IV Breast Cancer: Is That Still a Question? (June 2022, column)
Implications of the KEYNOTE-522 Trial for Patients with Early Stage Triple-Negative Breast Cancer (May 2022, column)
Implementation of Operative Standards into Surgical Practice (April 2022, column)
Clinical Trial Examines Postoperative Chemotherapy versus Observation in High-Risk Pancreatic Neuroendocrine Tumors (March 2022, column)
The Role of the Acute Care Surgeon in Caring for Patients with Cancer (February 2022, column)
Optimizing treatment of colorectal liver metastases through the use of clinical trial data (January 2022, column)
2021
Synoptic reporting for cancer surgery: Current requirements and future state (December 2021, column)
Tailoring systemic therapy for HER2+ early breast cancer—The CompassHER2 Trials (November 2021, column)
Improving patient-centered breast cancer treatment decisions (October 2021, column)
Role of radiation in the treatment of pancreatic adenocarcinoma in the neoadjuvant setting (September 2021, column)
Tips and strategies to maximize the use and impact of social media (August 2021, column)
Surgical oncology for the general surgeon (July 2021, column)
Surgical emergencies in advanced cancer patients: How to navigate a perilous time (June 2021, column)
Clinical trial for patients with incidentally discovered T2 or T3 gallbladder cancer: OPT-IN/EA2197 (May 2021, column)
Neoadjuvant immunotherapy: Results in melanoma show promise and pave the way for other solid tumors (April 2021, column)
2020
New trial aims to settle debate on the intensity of pancreatic cyst surveillance (October 2020, column)
ALLIANCE A021806 examines perioperative vs. adjuvant chemotherapy for resectable pancreatic cancer (October 2020, feature)
Ga-68 imaging changes clinical management of GI and pancreatic neuroendocrine tumors (July 2020, column)
Early-stage prostate cancer decision aids for diverse patient populations (April 2020, column)
The evolution of lung cancer surgery contributes to the sharpest drop in overall cancer mortality in the U.S. (April 2020, feature)
What is the National Clinical Trials Network, and how do I join? (March 2020, column)
ACS Clinical Research Program sessions at Clinical Congress 2019: A recap (February 2020, column)
Young-onset colorectal cancer: American Cancer Society issues new screening guidelines (February 2020, feature)
Modified FOLFIRINOX is superior to gemcitabine as adjuvant therapy for resected pancreatic cancer: The PRODIGE 24/CCTG PA6 Trial (January 2020, column)
Genetic testing for all breast cancer patients: Is this becoming a reality? (January 2020, feature)
